Search Result

Results for "

α-amylase/α-glucosidase Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (46) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Cholinesterase (ChE) (1) COX (2) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (1) Drug Intermediate (1) GLUT (1) Glycosidase (49) HDAC (1) Lipase (1) NF-κB (4) NOD-like Receptor (NLR) (2) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (1) Phosphatase (2) PPAR (2) Pregnane X Receptor (PXR) (1) Pyroptosis (2) Reference Standards (1) SARS-CoV (1) Tyrosinase (1) β-glucuronidase (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (6) Metabolic Disease (51) Neurological Disease (2)

By Targets:

Amylases (46)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Cholinesterase (ChE) (1)

COX (2)

Dipeptidyl Peptidase (3)

DNA/RNA Synthesis (1)

Drug Intermediate (1)

GLUT (1)

Glycosidase (49)

HDAC (1)

Lipase (1)

NF-κB (4)

NOD-like Receptor (NLR) (2)

P-glycoprotein (1)

P2Y Receptor (1)

p38 MAPK (1)

Phosphatase (2)

PPAR (2)

Pregnane X Receptor (PXR) (1)

Pyroptosis (2)

Reference Standards (1)

SARS-CoV (1)

Tyrosinase (1)

β-glucuronidase (1)

By Research Areas:

Cancer (5)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (6)

Metabolic Disease (51)

Neurological Disease (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132179

Fucoidan Maximum Cited Publications 6 Publications Verification	Glycosidase	Cardiovascular Disease Metabolic Disease Cancer
Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .

HY-126052

Gnetol	COX Tyrosinase HDAC	Metabolic Disease Cancer
Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC₅₀ of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC₅₀ of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .

HY-N2376

Chrysin-7-O-glucuronide 1 Publications Verification	Glycosidase Amylases NF-κB	Metabolic Disease Inflammation/Immunology
Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits *α-glucosidase* and *α-amylase* with IC₅₀ values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury .

HY-N6675

Gardenia yellow	Amylases Glycosidase	Inflammation/Immunology
Gardenia yellow is a competitive inhibitor of *α-Amylase* (HY-B2193) and *α-glucosidase. Gardenia yellow can bind to the catalytic sites of α-Amylase* and α-glucosidase, inhibit starch digestion, and significantly increase the contents of resistant starch and slowly digestible starch in starch-based systems. Gardenia yellow reduces the glycemic index and hydrolysis index. Gardenia yellow can be used in diabetes-related research .

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against *α-amylase, α-glucosidase, pancreatic lipase* and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-W005598

2-Hydroxyquinoline	Glycosidase Amylases	Metabolic Disease
2-Hydroxyquinoline is an inhibitor of *α-glucosidase* and *α-amylase* with IC₅₀ values of 64.4 µg/mL and 130.5 µg/mL, respectively. 2-Hydroxyquinoline can be used in the study of diabetes .

HY-N4309

Lotusine	Amylases Glycosidase	Neurological Disease Metabolic Disease Cancer
Lotusine is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against *α-amylase* and an IC₅₀ of 36.15 μg/mL against *α-glucosidase. Lotusine inhibits* the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

HY-200541

Dihydro-α-ionone	Others	Metabolic Disease
Dihydro-α-ionone is a volatile compound found in the essential oil of Persicaria hydropiper L. leaves. The essential oil can inhibit α-glucosidase and α-amylase activities .

HY-179141

α-Amylase/α-Glucosidase-IN-23	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-23 (Compound 5e) is a *α-Amylase/α-Glucosidase* inhibitor with IC₅₀ values of 73.68 nM for α-glucosidase and 146.18 nM for α-amylase. α-Amylase/α-Glucosidase-IN-23 can be used in the research of hypoglycemia .

HY-N9454

Garcinoic acid	Pregnane X Receptor (PXR) COX NF-κB Amylases β-glucuronidase DNA/RNA Synthesis Amyloid-β NOD-like Receptor (NLR) Pyroptosis	Cancer
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine *α-amylase, Saccharomyces cerevisiae α-glucosidase* and human DNA polymerase β (IC₅₀=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia .

HY-N10413

Diphlorethohydroxycarmalol	Glycosidase	Metabolic Disease
Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active *α-glucosidase* and *α-amylase* inhibitor with IC₅₀s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .

HY-179511

α-Glucosidase-IN-104	Glycosidase	Metabolic Disease
α-Glucosidase-IN-104 (Compound 9s) is an efficient inhibitor of *α-glucosidase* with an IC₅₀ of 24.32 μM. α-Glucosidase-IN-104 has a weak inhibitory effect on α-amylase and avoids gastrointestinal side effects. α-Glucosidase-IN-104 can be used for research on type 2 diabetes .

HY-W008168

Quinoline-2-carboxaldehyde 2-Quinolinecarboxaldehyde	Drug Intermediate	Others
Quinoline-2-carboxaldehyde (2-Quinolinecarboxaldehyde) is a quinoline derivative that serves as a synthetic precursor for Schiff base copper complexes. Quinoline-2-carboxaldehyde is applicable to research related to the synthetic design of biomaterials or organic compounds, such as fluorescent sensors .

HY-175605

α-Amylase/α-Glucosidase-IN-21	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-21 (Compound 4) is a dual-functional inhibitor of *α-Glucosidase* and *α-Amylase* with IC₅₀s of 0.27 and 0.19 µg/mL for α-Glucosidase and α-Amylase, respectively. α-Amylase/α-Glucosidase-IN-21 has an antidiabetic activity.α-Amylase/α-Glucosidase-IN-21 can be used for diabetes mellitus research .

HY-155241

α-Amylase/α-Glucosidase-IN-4	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-162673

α-Amylase/α-Glucosidase-IN-16	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-16 (compound 15) is a potent dual inhibitor of *α-amylase* and *α-Glucosidase* with IC₅₀ values of 0.8 and 1.2 μM, respectively. α-Amylase/α-Glucosidase-IN-16 can be used in the study of diabetes mellitus (DM) .

HY-W112651

2,4,6-Triphenylaniline	Glycosidase Amylases	Metabolic Disease
2,4,6-Triphenylaniline has anti-diabetic activity and can be encapsulated in nano-emulsions (NE) to enhance stability and permeability. The NE loaded with 2,4,6-Triphenylaniline inhibits *α-glucosidase* and *α-amylase* .

HY-146225

α-Amylase/α-Glucosidase-IN-2	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-2 (compound 5) is a potent *α-amylase* and *α-glucosidase* dual inhibitor with IC₅₀ values of 13.02, 13.09 µM for α-amylase and α-glucosidase, respectively. α-Amylase/α-Glucosidase-IN-2 has the potential for the research of diabetic complications .

HY-174319

α-Amylase/α-Glucosidase-IN-20	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of *α-Amylase* and *α-Glucosidase* with IC₅₀s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research .

HY-172622

α-Amylase/α-Glucosidase-IN-19	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-19 (compound 10) is a dual inhibitor of **α-amylase /α-glucosidase (IC₅₀**= 170.7 μM and 60.37 μM, respectively) .

HY-168961

α-Amylase/α-Glucosidase-IN-18	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-18 (Compound 9g) is the inhibitor for *α-Amylase* and *α-Glucosidase* with IC₅₀ of 49.17 nM and 10.71 nM. α-Amylase/α-Glucosidase-IN-18 can be used in research of type 2 diabetes mellitus .

HY-162634

α-Amylase/α-Glucosidase-IN-15	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-15 (compound 6C) is an oral bioactive inhibitor of *α-Glucosidase* and *α-amylase, with the IC₅₀*s of 21 μM and 61 μM, respectively .

HY-147711

α-Amylase/α-Glucosidase-IN-1	Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-1 (compound 33) is a potent *α-amylase/α-glucosidase* inhibitor with IC₅₀s of 2.01, 2.09 µM for α-amylase and α-glucosidase, respectively. Kinetic studies predict that α-Amylase/α-Glucosidase-IN-1 has the potential of anti hyperglycemia .

HY-161355

α-Amylase/α-Glucosidase-IN-9	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-9 (compound 5h) is a dual inhibitor for both *α-amylase* (IC₅₀ = 16.4 μM) and *α-glucosidase* (IC₅₀ = 31.6 μM) enzymes .

HY-149557

α-Amylase/α-Glucosidase-IN-5	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC₅₀s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .

HY-156380

α-Amylase/α-Glucosidase-IN-6	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of *α-amylase* and *α-glucosidase, with IC₅₀s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase*-IN-6 exhibits anti-hyperglycemic activities .

HY-162635

α-Amylase/α-Glucosidase-IN-14	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of *α-amylase* and *α-glucosidase, with the IC₅₀*s of 45.53 μM and 27.73 μM, respectively .

HY-172211

α-Amylase/α-Glucosidase-IN-17	Amylases Glycosidase	Metabolic Disease Cancer
α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of *α-amylase* and *α-glucosidase, with IC₅₀* values of 14.61 μM and 25.38 μM, respectively. α-Amylase/α-Glucosidase-IN-17 has certain inhibitory activity against A549 cancer cells. α-Amylase/α-Glucosidase-IN-17 has anti-tumor and anti-diabetic effects .

HY-162390

α-Amylase/α-Glucosidase-IN-11	Amylases Glycosidase	Endocrinology
α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits *α-amylase* (IC₅₀ = 30.39 μM) and *α-glucosidase* (IC₅₀ = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .

HY-162169

α-Amylase/α-Glucosidase-IN-8	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of *α-amylase* and *α-glucosidase, with IC₅₀s* of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC₅₀ = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .

HY-162036

α-Amylase/α-Glucosidase-IN-7	Glycosidase Amylases Cholinesterase (ChE)	Neurological Disease Metabolic Disease
α-Amylase/α-Glucosidase-IN-7 (Compound 3f) is a competitive *α-glucosidase* and *α-amylase* enzyme inhibitor with IC₅₀ values of 18.52 and 20.25 µM, respectively. α-Amylase/α-Glucosidase-IN-7 can also effectively inhibit AChE and BChE, with IC₅₀ values of 9.25 and 10.06 µM respectively. α-Amylase/α-Glucosidase-IN-7 can be used in diabetes and Alzheimer’s research .

HY-163439

α-Amylase/α-Glucosidase-IN-12	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-12 (compound 10k) is a dual inhibitor targeting α-glucosidase and α-amylase with IC₅₀ of 34.52 nM and 24.62 nM, respectively. α-Amylase/α-Glucosidase-IN-12 is an inhibitor designed based on triazolo[4,3-b][1,2,4]triazine and has the potential to be used in diabetes research .

HY-170796

α-Amylase-IN-11	Amylases	Metabolic Disease
α-Amylase-IN-11 (compound C5f) is an *α-Amylase* inhibitor (IC₅₀=0.56 μM) that can reduce the sugar level in vivo. α-Amylase-IN-11 has a moderate inhibitory effect on α-glucosidase (α-glucosidase), with IC₅₀=11.03 μM. α-Amylase-IN-11 can significantly reduce the glucose concentration in a mouse model and has the potential for use in diabetes research .

HY-162373

α-Amylase/α-Glucosidase-IN-10	Amylases Glycosidase P-glycoprotein	Metabolic Disease
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC₅₀: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .

HY-N11728

2,7"-Phloroglucinol-6,6'-bieckol	Amylases Glycosidase	Metabolic Disease
2,7"-Phloroglucinol-6,6'-bieckol is an orally active dual *α-amylase/α-glucosidase* inhibitor with IC₅₀ values of 6.94 μM and 23.35 μM respectively. 2,7"-Phloroglucinol-6, 6'-bieckol alleviates postprandial hyperglycemia in diabetic mice. 2,7"-Phloroglucinol-6,6'-bieckol can be used in diabetes research .

HY-N7729

Sekikaic acid	Amylases Glycosidase	Metabolic Disease
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-143268

HPA-IN-1	Amylases Glycosidase	Metabolic Disease
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .

HY-168495

α-Amylase-IN-12	Amylases Glycosidase	Metabolic Disease
α-Amylase-IN-12 (Compound 5e) is an *α-amylase* inhibitor (IC₅₀: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC₅₀ of 9.40 mM against *α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase*-IN-12 can be used for the research of diabetes .

HY-143269

HPA-IN-2	Amylases Glycosidase	Metabolic Disease
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .

HY-168944

ABCB1-IN-4	Amylases Glycosidase	Metabolic Disease
ABCB1-IN-4 (Compound C6z) is an orally active and potent dual *α-amylase* and *α-glucosidase* inhibitor with IC₅₀ values of 1.63 μM and 0.14 μM, respectively. ABCB1-IN-4 is promising for research of diabetes .

HY-168185

α-glucosidase/PTP1B-IN-1	Glycosidase Phosphatase Amylases	Metabolic Disease
α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent *α-glucosidase* and PTP1B inhibitor with an IC₅₀ value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against *α-amylase* with an IC₅₀ of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus .

HY-161429

Antidiabetic agent 5	Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of *α-glucosidase* and *α-amylase* with IC₅₀ values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .

HY-161764

α-Glucosidase-IN-67	Amylases Glycosidase	Metabolic Disease
α-Glucosidase-IN-67 (compound 5k) is a potent *α-Glucosidase* inhibitor with IC₅₀ values of 0.31, 4.51 µM for alpha-glucosidase and alpha-amylase, respectively. α-Glucosidase-IN-67 has the potential for the research of type-2 diabetes .

HY-N12688

2,3-Dihydrocalodenin B	Glycosidase Amylases	Metabolic Disease
2,3-Dihydrocalodenin B (Compound 6) is a compound that can be isolated from Knema globularia. 2,3-Dihydrocalodenin B is a potent and non-competitive inhibitor against *α-glucosidase* and *α-amylase, with IC₅₀* values of 1.1 and 2.6 μM, respectively. 2,3-Dihydrocalodenin B can be used for the research of diabetes .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glycosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, *α-amylase, and α-glucosidase* with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-161469

α-Amylase/α-Glucosidase-IN-13	Amylases Glycosidase	Metabolic Disease
α-Amylase/α-Glucosidase-IN-13 (Compound 5d) is a dual inhibitor of *α-Amylase/α-Glucosidase* that can be used for diabetes research .

HY-154972

α-Amylase/α-Glucosidase-IN-3	Glycosidase Amylases	Metabolic Disease
α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an *α-Amylase/α-Glucosidase* dual inhibitor, with IC₅₀s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus .

HY-159491

DPP-4-IN-11	Dipeptidyl Peptidase Glycosidase Amylases	Metabolic Disease
DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC₅₀=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of *α-glucosidase* (IC₅₀=3.02 μM) and *α-amylase* (IC₅₀=3.3 μM) .

HY-168074

4″-C18 EGCG	Amylases Glycosidase	Metabolic Disease Inflammation/Immunology
4″-C18 EGCG is a potent inhibitor of *α-amylase* and *α-glucosidase* with IC₅₀ values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .

HY-N4309A

Lotusine hydroxide	Amylases Glycosidase	Cardiovascular Disease
Lotusine hydroxide is an orally active signaling pathway modulator and enzyme inhibitor, with an IC₅₀ of 30.60 μg/mL against *α-amylase* and an IC₅₀ of 36.15 μg/mL against *α-glucosidase. Lotusine hydroxide inhibits* the EGFR-Akt-ERK signaling pathway by reducing the levels of phosphorylated EGFR, Akt and ERK. Lotusine hydroxide induces apoptosis, triggers G₀/G₁ cell cycle arrest and inhibits cancer cell proliferation. Lotusine hydroxide reduces lipid peroxidation and increases the activities of SOD, CAT and GPx. Lotusine hydroxide is applicable to researches related to non-small cell lung cancer, type 2 diabetes and autism spectrum disorder .

Cat. No.	Product Name	Type

HY-W005598

2-Hydroxyquinoline	Biochemical Assay Reagents
2-Hydroxyquinoline is an inhibitor of *α-glucosidase* and *α-amylase* with IC₅₀ values of 64.4 µg/mL and 130.5 µg/mL, respectively. 2-Hydroxyquinoline can be used in the study of diabetes .

HY-W008168

Quinoline-2-carboxaldehyde 2-Quinolinecarboxaldehyde	Biochemical Assay Reagents
Quinoline-2-carboxaldehyde (2-Quinolinecarboxaldehyde) is a quinoline derivative that serves as a synthetic precursor for Schiff base copper complexes. Quinoline-2-carboxaldehyde is applicable to research related to the synthetic design of biomaterials or organic compounds, such as fluorescent sensors .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks